循環器ジャーナル72巻3号

2024年07月発行

特集 心房細動—予防・早期発見・治療の進化 Ⅴ.抗凝固療法

DOAC登場でstrokeは減っているか？　日本人の適切な使用は？

著者： 碓井遼¹² 豊田一則¹

所属機関： ¹国立循環器病研究センター脳血管内科 ²北里大学医学部脳神経内科学

ページ範囲：P.444 - P.450

POINT
●非弁膜症性心房細動の脳梗塞予防として，従来のワルファリンよりもDOACの使用頻度が増えている．
●DOACはモニタリング不要で固定用量で使用可能だが，年齢や体重，腎機能に合わせた適切な投与量を遵守する．
●アブレーション後の経口抗凝固薬継続は脳梗塞再発と出血性イベントのリスクを勘案し，継続の有無を検討する．
●DOAC登場によって，心房細動関連虚血性脳卒中の発症率が低下した．

参考文献

1）Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-70.

2）Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving antico- agulation therapy--pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J 2015 ; 79 : 432-8.

3）日本循環器学会，日本不整脈心電学会．2020年改訂版 不整脈薬物治療ガイドライン．https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf（2024年4月閲覧）

4）Tripathi B, Arora S, Kumar V, et al. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States : an update from Nationwide Inpatient Sample database（2011-2014）. J Cardiovasc Electrophysiol 2018 ; 29 : 715-24.

5）Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management : results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation（AF）Patients Undergoing Catheter Ablation（COMPARE）randomized trial. Circulation 2014 ; 129 : 2638-44.

6）Calkins H, Willems S, Gerstenfeld EP, et al ; RE-CIRCUIT Investigators. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017 ; 376 : 1627-36.

7）Cappato R, Marchlinski FE, Hohnloser SH, et al ; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015 ; 36 : 1805-11.

8）Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018 ; 39 : 2942-55.

9）Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation : the ELIMINATE-AF trial. Eur Heart J 2019 ; 40 : 3013-21.

10）Kanaoka K, Nishida T, Iwanaga Y, et al. Oral anticoagulation after atrial fibrillation catheter ablation : benefits and risks. Eur Heart J 2024 ; 45 : 522-34.

11）Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions : a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015 ; 385 : 2077-87.

12）Larsen LK, Ovesen C, Frost L, et al. Trends in preadmission oral anticoagulant use and clinical outcome in atrial fibrillation patients admitted with acute stroke in Denmark. Eur Heart J Qual Care Clin Outcomes 2020 ; 6 : 112-20.

13）Forslund T, Komen JJ, Andersen M, et al. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke 2018 ; 49 : 2122-8.

14）Díaz-Guzmán J, Freixa-Pamias R, García-Alegría J, et al. Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain : first national population-based study 2005 to 2018. Rev Esp Cardiol（Engl Ed）2022 ; 75 : 496-505.

15）Yamashita Y, Uozumi R, Hamatani Y, et al. Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients—Fushimi AF Registry. Circ J 2017 ; 81 : 1278-85.

16）Zhang XL, Zhang XW, Wang TY, et al. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation : A Meta-Analysis. Circ Cardiovasc Qual Outcomes 2021 ; 14 : e007971.